Literature DB >> 6282194

Clinical pharmacology of cefotaxime in pediatric patients.

D A Kafetzis, D C Brater, J Kanarios, C A Sinaniotis, C J Papadatos.   

Abstract

Cefotaxime is a new cephalosporin with a spectrum of activity which may make it appropriate for use in pediatric patients. In 33 infants and children, administration of cefotaxime resulted in cure or improvement in 97% of patients, with eradication of 94% of isolated pathogens. Toxicity was minimal. The disposition of cefotaxime in this age group was similar to that reported for adults, with an elimination half-life of approximately 1.5 h, a volume of distribution of 1 liter/kg, a total serum clearance of 10 ml/min per kg, and a renal clearance of 6 ml/min per kg.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6282194      PMCID: PMC181728          DOI: 10.1128/AAC.20.4.487

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates.

Authors:  A J Sedman; J G Wagner
Journal:  J Pharm Sci       Date:  1976-07       Impact factor: 3.534

2.  Activity of HR 756 against Haemophilus influenzae, Bacteroides fragilis and Gram-negative rods.

Authors:  F A Drasar; W Farrell; A J Howard; C Hince; T Leung; J D Williams
Journal:  J Antimicrob Chemother       Date:  1978-09       Impact factor: 5.790

3.  Cefotoxime (HR 756) a new cephalosporin with exceptional broad-spectrum activity in vitro.

Authors:  J M Hamilton-Miller; W Brumfitt; A V Reynolds
Journal:  J Antimicrob Chemother       Date:  1978-09       Impact factor: 5.790

4.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

5.  Pharmacokinetics of cefotaxime.

Authors:  K P Fu; P Aswapokee; I Ho; C Matthijssen; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

6.  Metabolism of cefotaxime in animals and man.

Authors:  J Chamberlain; J D Coombes; D Dell; J M Fromson; R J Ings; C M Macdonald; J McEwen
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

7.  Cefotaxime in the treatment of severe paediatric infections.

Authors:  C J Papadatos; D A Kafetzis; J Kanarios
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

8.  Pharmacokinetics of cefotaxime in subjects with normal and impaired renal function.

Authors:  J P Fillastre; A Leroy; G Humbert; M Godin
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

9.  Human metabolism of cefotaxime.

Authors:  D S Reeves; L O White; H A Holt; D Bahari; M J Bywater; R P Bax
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

10.  Human pharmacology of cefotaxime (HR 756), a new cephalosporin.

Authors:  R Lüthy; R Münch; J Blaser; H Bhend; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

View more
  10 in total

1.  Aztreonam in the treatment of severe urinary tract infections in pediatric patients.

Authors:  F Rusconi; B M Assael; A Boccazzi; R Colombo; R M Crossignani; L Garlaschi; L Rancilio
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

Review 2.  A perspective on new beta-lactam antibiotics in pediatric patients.

Authors:  J D Nelson
Journal:  Bull N Y Acad Med       Date:  1984-05

Review 3.  Cefotaxime dosage in infants and children. Pharmacokinetic and clinical rationale for an extended dosage interval.

Authors:  G L Kearns; R A Young; R F Jacobs
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

4.  Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis.

Authors:  J M Trang; R F Jacobs; G L Kearns; A L Brown; T G Wells; F L Underwood; R B Kluza
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

Review 5.  Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.

Authors:  Jessica K Roberts; Chris Stockmann; Jonathan E Constance; Justin Stiers; Michael G Spigarelli; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

6.  Population Pharmacokinetic Model to Optimize Cefotaxime Dosing Regimen in Critically Ill Children.

Authors:  Agathe Béranger; Mehdi Oualha; Saïk Urien; Mathieu Genuini; Sylvain Renolleau; Radia Aboura; Déborah Hirt; Claire Heilbronner; Julie Toubiana; Jean-Marc Tréluyer; Sihem Benaboud
Journal:  Clin Pharmacokinet       Date:  2018-07       Impact factor: 6.447

7.  Cefotaxime pharmacokinetics and treatment of meningitis in neonates.

Authors:  R F Jacobs; G L Kearns
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

Review 8.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

9.  Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature.

Authors:  Stan J F Hartman; Roger J Brüggemann; Lynn Orriëns; Nada Dia; Michiel F Schreuder; Saskia N de Wildt
Journal:  Clin Pharmacokinet       Date:  2020-02       Impact factor: 6.447

10.  Optimal dosing of cefotaxime and desacetylcefotaxime for critically ill paediatric patients. Can we use microsampling?

Authors:  Yarmarly C Guerra Valero; Tavey Dorofaeff; Mark G Coulthard; Louise Sparkes; Jeffrey Lipman; Steven C Wallis; Jason A Roberts; Suzanne L Parker
Journal:  J Antimicrob Chemother       Date:  2022-07-28       Impact factor: 5.758

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.